Methotrexate intoxication: Beyond the adverse events
dc.contributor.buuauthor | Dalkılıç, Ediz | |
dc.contributor.buuauthor | Coşkun, Belkıs Nihan | |
dc.contributor.buuauthor | Yağız, Burcu | |
dc.contributor.buuauthor | Tufan, Ayşe Nur | |
dc.contributor.buuauthor | Ermurat, Selime | |
dc.contributor.buuauthor | Pehlivan, Yavuz | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0003-0298-4157 | tr_TR |
dc.contributor.researcherid | AAG-7155-2021 | tr_TR |
dc.contributor.researcherid | ABE-4424-2022 | tr_TR |
dc.contributor.researcherid | AAG-8227-2021 | tr_TR |
dc.contributor.scopusid | 6506739457 | tr_TR |
dc.contributor.scopusid | 55646165400 | tr_TR |
dc.contributor.scopusid | 57203458191 | tr_TR |
dc.contributor.scopusid | 56076552900 | tr_TR |
dc.contributor.scopusid | 55371331300 | tr_TR |
dc.contributor.scopusid | 13205593600 | tr_TR |
dc.date.accessioned | 2023-10-31T12:17:49Z | |
dc.date.available | 2023-10-31T12:17:49Z | |
dc.date.issued | 2018-08 | |
dc.description.abstract | Aim: Methotrexate (MTX) is the first-line disease-modifying antirheumatic drug in rheumatoid arthritis (RA). However, this anchor may cause some side effects that may range from nausea to mortality. The clinical features of MTX toxicity are under-researched. In this study, we aimed to find out the potential predisposing factors and outcomes of the MTX toxicity (n = 31). Methods: The data were collected from 31 patients whose ages ranged from 25 to 81 years, who were suffering from immune-mediated inflammatory diseases and major MTX-related toxicity. Results: Out of 31 patients, six (19.4%) used MTX every day, and 13 (41.9%) patients had renal insufficiency who were admitted to the hospital because of mucositis (90.3%) and fever (71%). While using MTX, 27 patients (87.1%) were discharged after the treatment and four patients (12.9%) died. Conclusions: Although MTX has high efficacy for the toxicity ratio, wrong use and dosage of MTX may be harmful to patients. Thus, patients should be informed about the proper use of MTX. | en_US |
dc.identifier.citation | Dalkılıç, E. vd. (2018). ''Methotrexate intoxication: Beyond the adverse events''. International Journal of Rheumatic Diseases, 21(8), 1557-1562. | en_US |
dc.identifier.endpage | 1562 | tr_TR |
dc.identifier.issn | 1756-1841 | |
dc.identifier.issn | 1756-185X | |
dc.identifier.issue | 8 | tr_TR |
dc.identifier.pubmed | 30146743 | tr_TR |
dc.identifier.scopus | 2-s2.0-85052205923 | tr_TR |
dc.identifier.startpage | 1557 | tr_TR |
dc.identifier.uri | https://doi.org/10.1111/1756-185X.13339 | |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/10.1111/1756-185X.13339 | |
dc.identifier.uri | http://hdl.handle.net/11452/34699 | |
dc.identifier.volume | 21 | tr_TR |
dc.identifier.wos | 000442740000011 | tr_TR |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wiley | en_US |
dc.relation.journal | International Journal of Rheumatic Diseases | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Rheumatology | en_US |
dc.subject | Methotrexate | en_US |
dc.subject | Methotrexate toxicity | en_US |
dc.subject | Renal insufficiency | en_US |
dc.subject | Low-dose methotrexate | en_US |
dc.subject | Rheumatoid-arthritis | en_US |
dc.subject | Acid supplementation | en_US |
dc.subject | Induced pancytopenia | en_US |
dc.subject | Folinic acid | en_US |
dc.subject | Toxicity | en_US |
dc.subject | Therapy | en_US |
dc.subject.emtree | Acemetacin | en_US |
dc.subject.emtree | Acetylsalicylic acid | en_US |
dc.subject.emtree | Antibiotic agent | en_US |
dc.subject.emtree | Diclofenac | en_US |
dc.subject.emtree | Filgrastim | en_US |
dc.subject.emtree | Folinate calcium | en_US |
dc.subject.emtree | Ibuprofen | en_US |
dc.subject.emtree | Indometacin | en_US |
dc.subject.emtree | Methotrexate | en_US |
dc.subject.emtree | Nonsteroid antiinflammatory agent | en_US |
dc.subject.emtree | Omeprazole | en_US |
dc.subject.emtree | Ramipril | en_US |
dc.subject.emtree | Antirheumatic agent | en_US |
dc.subject.emtree | Methotrexate | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Clinical article | en_US |
dc.subject.emtree | Coughing | en_US |
dc.subject.emtree | Death | en_US |
dc.subject.emtree | Disease predisposition | en_US |
dc.subject.emtree | Dose calculation | en_US |
dc.subject.emtree | Drug efficacy | en_US |
dc.subject.emtree | Drug information | en_US |
dc.subject.emtree | Drug intoxication | en_US |
dc.subject.emtree | Drug megadose | en_US |
dc.subject.emtree | Drug misuse | en_US |
dc.subject.emtree | Drug potentiation | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Fever | en_US |
dc.subject.emtree | Headache | en_US |
dc.subject.emtree | Hospital admission | en_US |
dc.subject.emtree | Hospital discharge | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Infection | en_US |
dc.subject.emtree | Inflammatory disease | en_US |
dc.subject.emtree | Kidney failure | en_US |
dc.subject.emtree | Longitudinal study | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Middle aged | en_US |
dc.subject.emtree | Mucosa inflammation | en_US |
dc.subject.emtree | Mycosis fungoides | en_US |
dc.subject.emtree | Nausea | en_US |
dc.subject.emtree | Open study | en_US |
dc.subject.emtree | Outcome assessment | en_US |
dc.subject.emtree | Patient risk | en_US |
dc.subject.emtree | Pneumonia | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Psoriatic arthritis | en_US |
dc.subject.emtree | Purpura | en_US |
dc.subject.emtree | Retrospective study | en_US |
dc.subject.emtree | Rheumatoid arthritis | en_US |
dc.subject.emtree | Sjoegren syndrome | en_US |
dc.subject.emtree | Systemic sclerosis | en_US |
dc.subject.emtree | Turkey (republic) | en_US |
dc.subject.emtree | Very elderly | en_US |
dc.subject.emtree | Chemically induced | en_US |
dc.subject.emtree | Communicable disease | en_US |
dc.subject.emtree | Dose response | en_US |
dc.subject.emtree | Drug interaction | en_US |
dc.subject.emtree | Fever | en_US |
dc.subject.emtree | Kidney failure | en_US |
dc.subject.emtree | Medication error | en_US |
dc.subject.emtree | Mortality | en_US |
dc.subject.emtree | Mucosa inflammation | en_US |
dc.subject.emtree | Risk assessment | en_US |
dc.subject.emtree | Risk factor | en_US |
dc.subject.emtree | Thrombocytopenic purpura | en_US |
dc.subject.emtree | Turkey (bird) | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Aged, 80 and over | en_US |
dc.subject.mesh | Antirheumatic agents | en_US |
dc.subject.mesh | Arthritis, rheumatoid | en_US |
dc.subject.mesh | Communicable diseases | en_US |
dc.subject.mesh | Dose-response relationship, drug | en_US |
dc.subject.mesh | Drug interactions | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Fever | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Medication errors | en_US |
dc.subject.mesh | Methotrexate | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Mucositis | en_US |
dc.subject.mesh | Purpura, thrombocytopenic | en_US |
dc.subject.mesh | Renal insufficiency | en_US |
dc.subject.mesh | Retrospective studies | en_US |
dc.subject.mesh | Risk assessment | en_US |
dc.subject.mesh | Risk factors | en_US |
dc.subject.mesh | Turkey | en_US |
dc.subject.scopus | Methotrexate; Rheumatoid Arthritis; Pustulosis Palmoplantaris | en_US |
dc.subject.wos | Rheumatology | en_US |
dc.title | Methotrexate intoxication: Beyond the adverse events | en_US |
dc.type | Article | |
dc.wos.quartile | Q4 | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: